We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of dalteparin administration on thrombin generation kinetics in healthy dogs.
- Authors
Gara‐Boivin, Carolyn; Castillo, Jérôme R.E.; Dunn, Marilyn E.; Bédard, Christian
- Abstract
Background Dalteparin is used to prevent thrombotic complications in dogs. Measurement of anti-factor Xa (anti-FXa) activity is currently used for monitoring therapy, but remains a nonfunctional test. The calibrated automated thrombogram ( CAT) could be a suitable approach for functional monitoring. Objectives We hypothesized that the CAT will detect decreased endogenous thrombin potential ( ETP) in healthy dogs receiving dalteparin. Methods Twenty-four healthy adult Beagles were randomly allocated to 4 equal groups. A single subcutaneous ( SC) dose of 50 U/kg, 100 U/kg, or 150 U/kg of dalteparin was given. Platelet-poor plasma ( PPP) was collected over a 24-hour period and evaluated by thrombin generation (TG) via CAT, anti-FXa activity, and APTT. Analysis was performed with a repeated-measures general linear mixed model, and the treated groups were compared to a placebo group. Results Time, dose, and time-dose interaction significantly affected ETP ( P < .0001 for all effects), peak ( P < .0001 for all effects), rate index ( P < .0006 for all effects), and anti- FXa activity ( P < .0001 for all effects). No significant time trend was detected in the control group. Dogs receiving the 100 U/kg dalteparin SC injection showed the most homogeneous response of ETP inhibition among treated groups. The % inhibition of ETP from baseline increased nonlinearly as a function of anti- FXa activity ( r2 = .8186). Conclusions The CAT assay can be employed to measure the effects of dalteparin at different doses in healthy dogs, showing sensitivity to time- and dose-dependent changes in ETP and other TG variables. Further investigation of the CAT as a tool for monitoring low molecular weight heparin therapy in dogs is warranted.
- Subjects
DALTEPARIN (Drug); THROMBIN regulation; ANIMAL health; DOGS; PHARMACODYNAMICS; HEPARIN
- Publication
Veterinary Clinical Pathology, 2017, Vol 46, Issue 2, p269
- ISSN
0275-6382
- Publication type
Article
- DOI
10.1111/vcp.12489